Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure
- PMID: 19919977
- DOI: 10.1161/CIRCHEARTFAILURE.109.861336
Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure
Abstract
Background: Urocortin 2 (Ucn2), a novel peptide with therapeutic potential in heart failure, and diuretics have opposing effects on renal function and the renin-angiotensin-aldosterone system. Because any prospective new treatment is likely to be used in conjunction with standard diuretic therapy, it is necessary to investigate the combined effects of these agents.
Methods and results: Ucn2 and furosemide were administered for 3 hours, both singly and combined, in 7 sheep with pacing-induced heart failure. Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide>Ucn2), urine sodium (furosemide>Ucn2), potassium (furosemide>Ucn2), and creatinine excretion (Ucn2>furosemide) and creatinine clearance (Ucn2>furosemide). Compared with furosemide treatment alone, Ucn2+furosemide produced a further diuresis (P<0.05), natriuresis (P<0.05), and a sustained increase in creatinine excretion (P<0.05) and clearance (P<0.05), without additional potassium elimination. All active treatments reduced mean arterial pressure (Ucn2+furosemide=furosemide>Ucn2), left atrial pressure (Ucn2+furosemide>Ucn2>furosemide), and peripheral resistance (Ucn2+furosemide=Ucn2>furosemide), whereas only Ucn2, singly and in combination with furosemide, increased cardiac output and dP/dt(max). In contrast to the increase in plasma renin activity elicited by furosemide alone, Ucn2 and Ucn2+furosemide markedly reduced plasma renin activity. All active treatments decreased plasma aldosterone (Ucn2+furosemide=Ucn2>furosemide), whereas only Ucn2 and Ucn2+furosemide reduced vasopressin and natriuretic peptide concentrations.
Conclusions: Ucn2 cotreatment with furosemide enhanced hemodynamic and renal function and diuretic responsiveness (without additional potassium depletion) in experimental heart failure. Furthermore, Ucn2 reversed furosemide-induced increases in plasma renin activity and induced greater decreases in plasma aldosterone and vasopressin. These data indicate that adjunct Ucn2 therapy with diuretics in heart failure is beneficial.
Similar articles
-
Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure.Clin Sci (Lond). 2008 May;114(10):635-42. doi: 10.1042/CS20070364. Clin Sci (Lond). 2008. PMID: 18052934
-
Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure.Circulation. 2005 Dec 6;112(23):3624-32. doi: 10.1161/CIRCULATIONAHA.105.561308. Circulation. 2005. PMID: 16330704
-
Interactions of enhanced urocortin 2 and mineralocorticoid receptor antagonism in experimental heart failure.Circ Heart Fail. 2013 Jul;6(4):825-32. doi: 10.1161/CIRCHEARTFAILURE.112.000205. Epub 2013 Jun 10. Circ Heart Fail. 2013. PMID: 23753530
-
Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators.Rev Cardiovasc Med. 2008 Winter;9(1):39-45. Rev Cardiovasc Med. 2008. PMID: 18418308 Review.
-
[ACE inhibition: mechanisms of cardioprotection in chronic experimental heart failure].Klin Wochenschr. 1991;69 Suppl 24:20-3. Klin Wochenschr. 1991. PMID: 1830909 Review. German.
Cited by
-
Urocortin 2 Gene Transfer for Systolic and Diastolic Dysfunction Due to Chronically Increased Left Ventricular Pressure.Hum Gene Ther. 2022 Oct;33(19-20):1091-1100. doi: 10.1089/hum.2022.132. Hum Gene Ther. 2022. PMID: 36053712 Free PMC article.
-
Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents.Drugs. 2011 Mar 26;71(5):515-25. doi: 10.2165/11585480-000000000-00000. Drugs. 2011. PMID: 21443277 Review.
-
Clinical perspectives of urocortin and related agents for the treatment of cardiovascular disease.Int J Endocrinol. 2012;2012:198628. doi: 10.1155/2012/198628. Epub 2012 Apr 3. Int J Endocrinol. 2012. PMID: 22548056 Free PMC article.
-
On Whether Ca-125 Is the Answer for Diagnosing Overhydration, Particularly in End-Stage Kidney Disease Patients-A Systematic Review.Int J Mol Sci. 2024 Feb 12;25(4):2192. doi: 10.3390/ijms25042192. Int J Mol Sci. 2024. PMID: 38396869 Free PMC article.
-
Distribution of urocortins and corticotropin-releasing factor receptors in the cardiovascular system.Int J Endocrinol. 2012;2012:395284. doi: 10.1155/2012/395284. Epub 2012 May 17. Int J Endocrinol. 2012. PMID: 22675352 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical